Tennis players must take sex test to play on women's tour under new WTA policy
The Women's Tennis Association (WTA) has introduced a new eligibility policy requiring all players to undergo genetic sex testing to compete on the tour. Starting in 2026, players must provide samples to confirm the absence of the SRY gene, with positive results triggering further medical assessment.
Why it matters
This policy marks a significant shift in sports governance regarding biological eligibility and inclusion, reflecting ongoing debates about fairness in women's professional sports.
Image source, Getty Images Image caption, Tennis is the latest sport to introduce genetic testing for women
The Women's Tennis Association (WTA) is to require all players to undergo genetic sex testing in order to compete on the WTA Tour.
In the latest edition of its women's eligibility policy, which will come into effect on Tuesday, players will be required to provide a cheek swab, blood or saliva sample to test for the presence of the SRY gene which is part of the Y chromosome and causes male characteristics to develop.
Players will be tested just once in their lifetime and only a negative result, showing no presence of the gene, will permit them to compete on the Tour.
If they test positive, players will face further medical assessment before being allowed to play.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in